Sawai Group Holdings Co., Ltd. (TYO:4887)

Japan · Delayed Price · Currency is JPY

1,747.50

+29.50 (1.72%)

Jul 6, 2026, 3:30 PM JST

-3.56% (1Y)

Market Cap	198.40B -3.5%
Revenue (ttm)	201.68B +6.7%
Net Income	10.44B -12.8%
EPS	81.52 -6.4%
Shares Out	115.49M
PE Ratio	19.07
Forward PE	10.49
Dividend	56.00 (3.26%)
Ex-Dividend Date	Mar 30, 2026

Volume	356,400
Open	1,718.00
Previous Close	1,718.00
Day's Range	1,710.00 - 1,758.50
52-Week Range	1,591.00 - 2,447.00
Beta	0.03
Analysts	Buy
Price Target	2,322.22 (+32.89%)
Earnings Date	Aug 10, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1929

Employees 3,310

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4887

Full Company Profile

Financial Performance

In fiscal year 2026, Sawai Group Holdings's revenue was 201.68 billion, an increase of 6.69% compared to the previous year's 189.02 billion. Earnings were 10.44 billion, a decrease of -12.79%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for 4887 stock is "Buy." The 12-month stock price target is ¥2,322, which is an increase of 32.89% from the latest price.

Price Target

¥2,322

(32.89% upside)

Analyst Consensus: Buy

Stock Forecasts